Claims
- 1. A method of identifying a nucleic acid molecule associated with a viral disease comprising:
a) contacting a sample comprising nucleic acid molecules with a hybridization probe comprising at least 25 contiguous nucleotides of SEQ ID NO:1; and b) detecting the presence of a nucleic acid molecule in said sample that hybridizes to said probe, thereby identifying a nucleic acid molecule associated with a viral disease.
- 2. The method of claim 1, wherein said hybridization probe is detectably labeled.
- 3. The method of claim 1, wherein said sample comprising nucleic acid molecules is subjected to agarose gel electrophoresis and southern blotting prior to contacting with said hybridization probe.
- 4. The method of claim 1, wherein said sample comprising nucleic acid molecules is subjected to agarose gel electrophoresis and northern blotting prior to contacting with said hybridization probe.
- 5. The method of claim 1, wherein said detecting is by in situ hybridization.
- 6. A method of identifying a nucleic acid associated with a viral disease comprising:
a) contacting a sample comprising nucleic acid molecules with a first and a second amplification primer, said first primer comprising at least 25 contiguous nucleotides of SEQ ID NO:1 and said second primer comprising at least 25 contiguous nucleotides from the complement of SEQ ID NO:1; b) incubating said sample under conditions that allow nucleic acid amplification; and c) detecting the presence of a nucleic acid molecule in said sample that is amplified, thereby identifying a nucleic acid molecule associated with a viral disease.
- 7. The method of claim 6, wherein said sample comprising nucleic acid molecules is subjected to agarose gel electrophoresis after said incubation step.
- 8. The method of any one of claims 1 or 6, wherein said method is used to detect mRNA in said sample.
- 9. The method of any one of claims 1 or 6, wherein said method is used to detect genomic DNA in said sample.
- 10. A method of identifying a polypeptide associated with a viral disease comprising:
a) contacting a sample comprising polypeptides with a PLD 55092 binding substance; and b) detecting the presence of a polypeptide in said sample that binds to said PLD 55092 binding substance, thereby identifying a polypeptide associated with a viral disease.
- 11. The method of claim 10, wherein said binding substance is an antibody.
- 12. The method of claim 10, wherein said binding substance is detectably labeled.
- 13. A method of identifying a subject having a viral disease, or at risk for developing a viral disease comprising:
a) contacting a sample obtained from said subject comprising nucleic acid molecules with a hybridization probe comprising at least 25 contiguous nucleotides of SEQ ID NO:1; and b) detecting the presence of a nucleic acid molecule in said sample that hybridizes to said probe, thereby identifying a subject having a viral disease, or at risk for developing a viral disease.
- 14. The method of claim 13, wherein said hybridization probe is detectably labeled.
- 15. The method of claim 13, wherein said sample comprising nucleic acid molecules is subjected to agarose gel electrophoresis and southern blotting prior to contacting with said hybridization probe.
- 16. The method of claim 13, wherein said sample comprising nucleic acid molecules is subjected to agarose gel electrophoresis and northern blotting prior to contacting with said hybridization probe.
- 17. The method of claim 13, wherein said detecting is by in situ hybridization.
- 18. A method of identifying a subject having a viral disease, or at risk for developing a viral disease comprising:
a) contacting a sample obtained from said subject comprising nucleic acid molecules with a first and a second amplification primer, said first primer comprising at least 25 contiguous nucleotides of SEQ ID NO:1 and said second primer comprising at least 25 contiguous nucleotides from the complement of SEQ ID NO:1; b) incubating said sample under conditions that allow nucleic acid amplification; and c) detecting the presence of a nucleic acid molecule in said sample that is amplified, thereby identifying a subject having a viral disease, or at risk for developing a viral disease.
- 19. The method of claim 18, wherein said sample comprising nucleic acid molecules is subjected to agarose gel electrophoresis after said incubation step.
- 20. The method of any one of claims 13 or 18, wherein said method is used to detect mRNA in said sample.
- 21. The method of any one of claims 13 or 18, wherein said method is used to detect genomic DNA in said sample.
- 22. A method of identifying a subject having a viral disease, or at risk for developing a viral disease comprising:
a) contacting a sample obtained from said subject comprising polypeptides with a PLD 55092 binding substance; and b) detecting the presence of a polypeptide in said sample that binds to said PLD 55092 binding substance, thereby identifying a subject having a viral disease, or at risk for developing a viral disease.
- 23. The method of claim 22, wherein said binding substance is an antibody.
- 24. The method of claim 22, wherein said binding substance is detectably labeled.
- 25. A method for identifying a compound capable of treating a viral disease characterized by aberrant PLD 55092 nucleic acid expression or PLD 55092 polypeptide activity comprising assaying the ability of the compound to modulate PLD 55092 nucleic acid expression or PLD 55092 polypeptide activity, thereby identifying a compound capable of treating a viral disease characterized by aberrant PLD 55092 nucleic acid expression or PLD 55092 polypeptide activity.
- 26. The method of claim 25, wherein the disease is a disease associated with herpes simplex virus infection.
- 27. The method of claim 25, wherein the disease is a disease associated with hepatitis B virus infection.
- 28. The method of claim 25, wherein the disease is a disease associated with hepatitis C virus infection.
- 29. The method of claim 25, wherein the ability of the compound to modulate the activity of the PLD 55092 polypeptide is determined by detecting the induction of an intracellular second messenger.
- 30. A method for treating a subject having a viral disease characterized by aberrant PLD 55092 polypeptide activity or aberrant PLD 55092 nucleic acid expression comprising administering to the subject a PLD 55092 modulator, thereby treating said subject having a viral disease.
- 31. The method of claim 30, wherein the PLD 55092 modulator is a small molecule.
- 32. The method of claim 30, wherein the disease is a disease associated with herpes simplex virus infection.
- 33. The method of claim 30, wherein the disease is a disease associated with hepatitis B virus infection.
- 34. The method of claim 30, wherein the disease is a disease associated with hepatitis C virus infection.
- 35. The method of claim 30, wherein said PLD 55092 modulator is administered in a pharmaceutically acceptable formulation.
- 36. The method of claim 30, wherein said PLD 55092 modulator is administered using a gene therapy vector.
- 37. The method of 30, wherein the PLD 55092 modulator is capable of modulating PLD 55092 polypeptide activity.
- 38. The method of claim 37, wherein the PLD 55092 modulator is an anti-PLD 55092 antibody.
- 39. The method of claim 37, wherein the PLD 55092 modulator is a PLD 55092 polypeptide comprising the amino acid sequence of SEQ ID NO:2, or a fragment thereof.
- 40. The method of claim 37, wherein the PLD 55092 modulator is a PLD 55092 polypeptide comprising an amino acid sequence which is at least 90 percent identical to the amino acid sequence of SEQ ID NO:2, wherein said percent identity is calculated using the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.
- 41. The method of claim 37, wherein the PLD 55092 modulator is an isolated naturally occurring allelic variant of a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a complement of a nucleic acid molecule consisting of SEQ ID NO:1 or SEQ ID NO:3 at 4× SSC at 65-70° C. followed by one or more washes in 1× SSC at 65-70° C.
- 42. The method of claim 30, wherein the PLD 55092 modulator is capable of modulating PLD 55092 nucleic acid expression.
- 43. The method of claim 42, wherein the PLD 55092 modulator is an antisense PLD 55092 nucleic acid molecule.
- 44. The method of claim 42, wherein the PLD 55092 modulator is a ribozyme.
- 45. The method of claim 42, wherein the PLD 55092 modulator comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, or a fragment thereof.
- 46. The method of claim 42, wherein the PLD 55092 modulator comprises a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence which is at least 90 percent identical to the amino acid sequence of SEQ ID NO:2, wherein said percent identity is calculated using the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.
- 47. The method of claim 42, wherein the PLD 55092 modulator comprises a nucleic acid molecule encoding a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule which hybridizes to a complement of a nucleic acid molecule consisting of SEQ ID NO:1 or SEQ ID NO:3 at 4× SSC at 65-70° C. followed by one or more washes in 1× SSC, at 65-70° C.
- 48. A method for identifying a compound capable of modulating a virus activity comprising:
a) contacting a virus or a virus infected cell with a test compound; and b) assaying the ability of the test compound to modulate the expression of a PLD 55092 nucleic acid or the activity of a PLD 55092 polypeptide; thereby identifying a compound capable of modulating a virus activity.
- 49. The method of claim 48, wherein said virus activity is virus replication.
- 50. The method of claim 48, wherein said virus activity is virus envelopment.
- 51. The method of claim 48, wherein said virus activity is extracellular virion formation.
- 52. The method of claim 48, wherein said virus activity is cell-cell virus transmission.
- 53. A method for modulating a virus activity comprising contacting a virus or a virus infected cell with a PLD 55092 modulator, thereby modulating said virus activity.
- 54. The method of claim 53, wherein the PLD 55092 modulator is a small molecule.
- 55. The method of claim 53, wherein said virus activity is virus replication.
- 56. The method of claim 53, wherein said virus activity is virus envelopment.
- 57. The method of claim 53, wherein said virus activity is extracellular virion formation.
- 58. The method of claim 53, wherein said virus activity is cell-cell virus transmission.
- 59. The method of claim 53, wherein the PLD 55092 modulator is capable of modulating PLD 55092 polypeptide activity.
- 60. The method of claim 59, wherein the PLD 55092 modulator is an anti-PLD 55092 antibody.
- 61. The method of claim 59, wherein the PLD 55092 modulator is a PLD 55092 polypeptide comprising the amino acid sequence of SEQ ID NO:2, or a fragment thereof.
- 62. The method of claim 59, wherein the PLD 55092 modulator is a PLD 55092 polypeptide comprising an amino acid sequence which is at least 90 percent identical to the amino acid sequence of SEQ ID NO:2, wherein said percent identity is calculated using the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.
- 63. The method of claim 59, wherein the PLD 55092 modulator is an isolated naturally occurring allelic variant of a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a complement of a nucleic acid molecule consisting of SEQ ID NO:1 or SEQ ID NO:3 at 4× SSC at 65-70° C. followed by one or more washes in 1× SSC, at 65-70° C.
- 64. The method of claim 53, wherein the PLD 55092 modulator is capable of modulating PLD 55092 nucleic acid expression.
- 65. The method of claim 64, wherein the PLD 55092 modulator is an antisense PLD 55092 nucleic acid molecule.
- 66. The method of claim 64, wherein the PLD 55092 modulator is a ribozyme.
- 67. The method of claim 64, wherein the PLD 55092 modulator comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, or a fragment thereof.
- 68. The method of claim 64, wherein the PLD 55092 modulator comprises a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence which is at least 90 percent identical to the amino acid sequence of SEQ ID NO:2, wherein said percent identity is calculated using the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.
- 69. The method of claim 64, wherein the PLD 55092 modulator comprises a nucleic acid molecule encoding a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule which hybridizes to a complement of a nucleic acid molecule consisting of SEQ ID NO:1 or SEQ ID NO:3 at 4× SSC at 65-70° C. followed by one or more washes in 1× SSC, at 65-70° C.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application Serial No. 60/254,037, filed Dec. 7, 2000, the entire contents of which are incorporated herein by this reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60254037 |
Dec 2000 |
US |